Perspective Therapeutics Inc.
CATX | AMEX
$2.97
+$0.09 (+3.13%)
At close: Sep 21, 2026, 4:00 PM ET
$2.98
+$0.01 (+0.34%)
After-hours:
Sep 21, 2026, 7:57 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Jun 29, 2022 | FY 2020 Jun 29, 2021 |
|---|---|---|---|---|---|---|
Revenue | n/a | 1.45M | 1.43M | 7.1M | 10.8M | 10.05M |
Cost of Revenue | n/a | n/a | n/a | 5.47M | 6.18M | 4.93M |
Gross Profit | n/a | -852K | 1.43M | 1.63M | 4.62M | 5.12M |
Operating Income | -113.56M | 10.46M | -40.94M | -15.18M | -7.39M | -3.44M |
Interest Income | 8.11M | 10.52M | 934K | 1.12M | 119K | 59K |
Pretax Income | -104.43M | -81.38M | -40.11M | -14.67M | -7.27M | -3.39M |
Net Income | -103.12M | -79.28M | -46.51M | -14.67M | -7.15M | -3.19M |
Selling & General & Admin | 30.23M | 26.61M | 21.06M | 14.21M | 9.43M | 7.13M |
Research & Development | 84.22M | 41.64M | 21.31M | 2.6M | 2.58M | 1.43M |
Other Expenses | -884K | 24.09M | n/a | n/a | n/a | n/a |
Operating Expenses | 113.56M | 92.34M | 42.38M | 17.43M | 12.01M | 8.56M |
Interest Expense | 376K | -48K | 84K | n/a | 119K | n/a |
Selling & Marketing Expenses | n/a | n/a | 97K | 3.23M | 2.8M | 2.44M |
Cost & Expenses | 113.56M | 90.89M | 42.38M | 22.9M | 18.19M | 13.49M |
Income Tax Expense | -793K | -2.1M | -2.65M | n/a | -119K | -199K |
Shares Outstanding (Basic) | 73.81M | 64.43M | 54.91M | 54.91M | 54.91M | 54.91M |
Shares Outstanding (Diluted) | 73.81M | 64.43M | 54.91M | 54.91M | 54.91M | 54.91M |
EPS (Basic) | -1.40 | -1.23 | -0.85 | -0.27 | -0.13 | -0.06 |
EPS (Diluted) | -1.40 | -1.23 | -0.85 | -0.27 | -0.13 | -0.06 |
EBITDA | -100.8M | 10.46M | -39.96M | -14.84M | -7.39M | -3.43M |
EBIT | -104.05M | -81.42M | -40.94M | -15.18M | -7.39M | -3.44M |
Depreciation & Amortization | 3.25M | 2.31M | 981K | 344K | 248K | 9K |
Add to Watchlist
Select watchlists to add or remove CATX